TABLE III

FROM:

The Increased Risk of Skin Cancer Is Persistent After Discontinuation of Psoralen+Ultraviolet A: A Cohort Study

Tamar E C Nijsten and Robert S Stern

Table III. Univariate analysis of potential risk factors associated with development of SCC and BCC in patients in the PUVA Follow-up Study (n=1380)

	SCC		BCC
	IRR	95% CI	IRR	95% CI
Age (y)
<45	1a		1a
45–64	3.76	3.02–4.70	3.82	2.91–5.02
>64	6.64	5.22–8.44	12.26	9.27–16.21
Men, compared with women	1.53	1.27–1.83	2.54	2.07–3.12
Skint ype, compared with:
III–VI	1a		1a
I–II	1.67	1.40–2.01	1.17	0.96–1.44
Region
North	1a		1a
Middle	0.59	0.47–0.76	0.97	0.75–1.25
South	1.15	0.94–1.41	1.33	1.07–1.65
Years since stopping Puva
< 2 y	1A		1A
2–5 y	1.73	1.38–2.17	2.63	2.03–3.39
6–10 y	1.54	1.21–1.96	3.41	2.62–4.43
11–15 y	1.46	1.11–1.94	3.44	2.55–4.64
>15 y	1.06	0.77–1.46	3.79	2.75–5.23
High methotrexate exposure (36+mo) compared with low	3.26	2.66, 3.99	2.03	1.61–2.56
High tar (45+mo) and/or UVB exposure (300+treatments) compared with low	1.94	1.62–2.33	2.31	1.90–2.81
X-ray therapy prior to entering study compared with none	2.37	1.96–2.87	2.33	1.90–2.86
No. of PUVA treatments
< 100	1a		1a
100–199	3.99	3.21–4.98	2.39	1.90–3.00
200–299	7.67	6.00–9.80	3.52	2.69–4.62
300–399	12.09	8.98–16.29	4.96	3.52–6.98
400–499	19.24	13.22–28.00	5.69	3.63–8.90
500	29.83	20.99–42.40	9.59	6.36–14.47
No. of PUVA treatments during first 5 y of study
< 100	1a		1a
100–199	2.70	2.24–3.25	1.77	1.44–2.17
200	5.47	4.31–6.93	2.25	1.72–2.94
Period
1975–80	1a		1ai>
1981–85	2.17	1.64–2.88	2.51	1.89–3.34
1986–90	4.01	3.05–5.28	4.48	3.42–5.86
1991–95	7.51	5.70–9.90	10.30	7.99–13.28
1996–2000	11.09	8.34–14.73	11.93	9.24–15.41

^a Base stratum.